laninamivir

an antiviral agent

Also Known As:

5-(acetylamino)-4-((aminoiminomethyl)amino)-2,6-anhydro-3,4,5-trideoxy-7-O-methyl-D-glycero-D-galacto-non-2-enonic acid; R 125489; R-125489; R125489; laninamivir octanoate; laninamivir octanoate hydrate; laninamivir octanoate monohydrate; laninamivir trifluoroacetate

Networked: 121 relevant articles (17 outcomes, 22 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Ikematsu, Hideyuki: 15 articles (07/2022 - 10/2011)
2.	Kashiwagi, Seizaburo: 15 articles (07/2022 - 08/2012)
3.	Kawai, Naoki: 13 articles (07/2022 - 10/2011)
4.	Iwaki, Norio: 11 articles (07/2022 - 05/2013)
5.	Yamashita, Makoto: 8 articles (08/2019 - 01/2009)
6.	Kubo, Shuku: 7 articles (08/2019 - 01/2009)
7.	Hurt, Aeron C: 6 articles (01/2016 - 11/2013)
8.	Watanabe, Akira: 6 articles (01/2016 - 09/2010)
9.	Hirotsu, Nobuo: 5 articles (02/2021 - 05/2013)
10.	Tomozawa, Takanori: 5 articles (08/2019 - 01/2009)

Related Diseases

1.	Human Influenza (Influenza) 12/01/2016 - "We conducted a double-blind, multicenter, randomized, placebo-controlled study to determine whether the efficacy of a single 20-mg dose of inhaled laninamivir octanoate to prevent the development of influenza was superior to that of placebo as prophylaxis for influenza in pediatric (<10 years) household members of index cases. " 02/01/2014 - "These results show that laninamivir was effective for the treatment of both influenza A(H3N2) and B in this study, with no safety issues. " 01/01/2018 - "Laninamivir octanoate is effective in preventing influenza in post-exposure settings as compared to placebo." 12/01/2016 - "A single 20-mg dose of inhaled laninamivir octanoate is an effective treatment of influenza. " 12/01/2014 - "These results suggest that laninamivir continued to be effective against influenza A(H3N2) with no safety issues and that it is unlikely that the clinical use of laninamivir will lead to virus resistance."
2.	Infections 01/01/2013 - "The objectives of this study were to model the population pharmacokinetics of LO and its active metabolite laninamivir after inhaled administration of LO using a pooled population of healthy subjects, and adult and pediatric patients with influenza virus infection from 8 clinical studies, and to evaluate covariate effects on pharmacokinetics. " 01/01/2018 - "Thus, similarly to the DPI, ELF concentration profiles of laninamivir after a single nebulized administration support its long-lasting effect against influenza virus infection. " 01/01/2017 - "The patient was diagnosed with influenza A virus infection, and then given laninamivir octanoate hydrate. " 06/01/2014 - "After inhaled administration, LO exhibits clinical efficacy for both treatment and prophylaxis of influenza virus infection, resulting from hydrolytic bioactivation into its pharmacologically active metabolite laninamivir in the pulmonary tissue. " 04/01/2013 - "Despite laninamivir requiring only the administration of a single dose, it was confirmed to be an effective treatment in more than 90 % of patients with type A or type B influenza virus infections. "
3.	Fever (Fevers) 09/01/2018 - "The median durations of fever and symptoms after laninamivir inhalation were quite consistent for the six studied seasons for A (H1N1)pdm09, A (H3N2), and B, without any significant differences. " 09/01/2017 - "Fever resolution after laninamivir inhalation was similar in all comparisons of the 2011/12 to 2015/16 seasons for both A(H3N2) and B, with no significant difference among the five seasons. " 09/01/2017 - "Fever resolution after laninamivir inhalation by the A(H1N1)pdm09 patients was similar in the 2013/14 and 2015/16 seasons. " 07/01/2022 - "Duration of fever and other symptoms after the inhalation of laninamivir octanoate hydrate: A study of the 2017/18 and 2018/19 seasons and comparison with the 2011/12 to 2016/17 Japanese influenza seasons." 09/01/2018 - "Duration of fever and other symptoms after the inhalation of laninamivir octanoate hydrate in the 2016/17 Japanese influenza season; comparison with the 2011/12 to 2015/16 seasons."
4.	Body Weight (Weight, Body) 01/01/2013 - "Body weight was identified to affect distribution volumes of LO and laninamivir and the metabolic clearance of LO; however there was no notable effect on exposures across the wide body weight range evaluated. " 11/01/2009 - "In this study, the tissue distribution profiles after a single intranasal administration of CS-8958 (0.5 micromol/kg of body weight) to mice were investigated, focusing especially on the retention of CS-8958 in the respiratory tract by comparing it with R-125489 and a marketed drug, zanamivir. "
5.	Inflammation (Inflammations) 08/01/2019 - "Efficacy of laninamivir octanoate in mice with advanced inflammation stage caused by infection of highly lethal influenza virus."

Related Drugs and Biologics

1.	Oseltamivir (Tamiflu)
2.	Neuraminidase (Sialidase)
3.	Zanamivir (Relenza)
4.	laninamivir
5.	peramivir
6.	CS 8958
7.	Antiviral Agents (Antivirals)
8.	favipiravir
9.	brincidofovir
10.	DNA Primase (Primase)

Related Therapies and Procedures

1.	Intranasal Administration
2.	Therapeutics
3.	Intravenous Administration
4.	Dry Powder Inhalers
5.	Inhalation Administration